The Alliance for Regenerative Medicine Releases Agenda for Sixth Annual Advanced Therapies Summit

– March 17, 2016

WASHINGTON, DC, March 17, 2016 – The Alliance for Regenerative Medicine (ARM) today released the complete agenda for its sixth annual Advanced Therapies Summit, taking place April 6, 2016 in Stockholm, Sweden. This one-day meeting is a gathering of the sector’s top executives, clinical researchers and policymakers across Europe and the United States to discuss how best to support the Advanced Therapies Medicinal Products (ATMP) sector.

This multi-stakeholder, interactive forum features five roundtable discussions led by sector experts representing international advanced therapies organizations in the gene therapy, cell therapy and regenerative medicine community. The event also offers attendees ample networking opportunities to engage with other sector stakeholders, including top company executives, clinical researchers, public policymakers and other members of the advanced therapies community.

“The Advanced Therapies Summit provides the perfect opportunity for discussion and the exchange of ideas within the ATMP community,” said Alexander Vos, CEO of PharmaCell. “This forum will cover the most pressing issues our sector is facing today, the timing couldn’t be better. PharmaCell is very pleased to be able to support this vital interaction.”

2016 Roundtables and Discussion Leaders:

Roundtable I: Industrialization of Cell Therapy
Sylvain Arnould, Head of Manufacturing, Cellectis
Dieter Hauwaerts, Vice President of Operations, Celyad
Keith Thompson, CEO, Cell and Gene Therapy Catapult
Giuliana Vallanti, Ph.D., Head of Development and Quality Control, MolMed
Phil Vanek, Ph.D., General Manager, Cell Bioprocessing, GE Healthcare Life Sciences

Roundtable II: ATMP Development & Regulatory Challenges
Eduardo Bravo, CEO, TiGenix
Anne-Virginie Eggimann, Vice President, Regulatory Science, bluebird bio
Paula Salmikangas, Ph.D., Chair, Committee for Advanced Therapies (CAT), European Medicines Agency (EMA) 
Carmen Vieira, Pharm.D., Associate Director of Regulatory Affairs – EMEA, Janssen Research & Development

Roundtable III: Pharma’s Strategic Investment in Gene & Cell Therapy
Sven Kili, Gene Therapy Development Head, GlaxoSmithKline
Edward Lanphier, CEO, Sangamo BioSciences
Mathieu Simon, M.D., Executive Vice President, Chief Operating Officer, Cellectis
Jeff Till, Ph.D., Director, External Innovation, EMD Serono

Roundtable IV: Adaptive Pathways & Early Market Access
Francis Arickx, Head of Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance
Doug Danison, Head of Global Pricing, Reimbursement, Market Access, and Health Economics, bluebird bio
Leeza Osipenko, Ph.D., Associate Director of Scientific Advice, National Institute for Health & Care Excellence (NICE)
Yaron Ramati, Director of Regulatory Affairs, Pluristem Therapeutics
Constantinos Ziogas, Principal Administrator, European Medicines Agency (EMA)

Roundtable V: ATMP Product Reimbursement
Francis Arickx, Head of Directorate Pharmaceutical Policy, National Institute for Health and Disability Insurance
Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult
Eric Faulkner, Vice President, Precision and Transformative Technology Solutions, Evidera
Alec Orphanidis, SVP, Global Commercial Operations, uniQure
Leeza Osipenko, Ph.D., Associate Director of Scientific Advice, National Institute for Health & Care Excellence (NICE)

Sponsors for the 2016 Advanced Therapies Summit include PharmaCell; TiGenix and TrakCel.

Registration is now open – to learn more and to secure a spot, please visit ARM’s event page. For members of the media interested in attending, please contact Lyndsey Scull ( for information regarding complimentary press registration.

The event will be held at the Scandic Victoria Tower; Arne Beurlings Torg 3; 164 40 Kista, Sweden. 

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit